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ABSTRACT
1-[3-(Furo[3,2-C]quinolin-4-ylamino)phenyl]ethanoe-O-methyl-oxime (CCK3) is an antitumor agent, particularly active against the
growth of the renal cancer cell, UO-31, and two melanoma cancer cells, UACC-257 and UACC-62, as indicated in the NCI’s full panel
of 60 human cancer cell lines cytotoxicity evaluation. From the structure-activity relationships between amsacrine and CCK3, CCK3
was expected to have longer half-life than amsacrine in plasma. Therefore, a reversed-phase high performance liquid chromatography
method was developed and validated for the determination of pharmacokinetics of CCK3 in rats. The plasma samples were spiked with
the internal standard 2-naphthol and extracted using dichloromethane. A C18 column (55 × 4 mm) was used for the separation of
analytes with a mobile phase consisted of 30% acetonitrile, 5% tetrahydrofuran and 65% pH 3.0 of McIlvaine buffer at a flow rate of
1.0 mL/min. CCK3 was detected and utilized by electrochemical detector at 1.0 voltage and 10 nA. Intra- and inter-day precision and
accuracy were acceptable down to the limit of quantitation of 10 ng/mL. The lower limit of detection was 5 ng/mL. As for the in vivo
study, the pharmacokinetic parameters of CCK3 in rats after intravenous administration of 3.97 and 7.94 mg/kg were determined. The
apparent volume of distribution, half-life and clearance showed no significant difference between these two dosages. The area under
the plasma concentration time curve increased proportionally with increase in dose. The half-life of CCK3 was prolonged 3 folds,
compared to amsacrine. Therefore, CCK3 might have the potential to be tested clinically.
Key words: 1-[3-(furo[3,2-C]quinolin-4-ylamino)phenyl]-ethanoe-O-methyl-oxime, amsacrine, antitumor, pharmacokinetics, half-life

INTRODUCTION
Amsacrine is a substituted 9-aminoacridine derivative
which has clinical activity against acute lymphocytic and
nonlymphocytic leukemias(1-5). However, the half-life of
amsacrine in plasma is relatively short about 0.5 hr,
resulting in inconvenient clinical use(6). Therefore, a series
of structure-activity relationships (SAR) studies had been
conducted to obtain a drug with potent antitumor activity
and longer half-life in human plasma(7-11). The major route
of breakdown for amsacrine and its analogs in vivo is a
nonenzymatically mediated attack of thiol at C(9), eventually resulting in loss of the side chain and the formation of
inactive products(12-14). The furo[2,3-b]quinoline possessing a higher electron density than that of acridine was used
to replace acridine, and obtained a 4-anilinofuro[2,3b]quinoline derivative with a longer half-life(11,15). In the
structure- activity relationships studies, a series of 4-anilino
furo[2,3-b]quinoline derivatives with expected longer halflife in plasma have been synthesized(16). Among these
* Author for correspondence. Tel: +886-7-3121101 ext. 2166, 2261;
Fax: +886-7-3210683; E-mail: yhtsai@kmu.edu.tw

derivatives, 1-[3-(furo[3,2-c]quinolin-4-ylamino)phenyl]ethanoe-O-methyl-oxime (CCK3) was found to be especially active against the growth of one renal cancer cell, UO-31
(GI50 < 0.01 µM), and two melanoma cancer cells, UACC257 (GI50 = 0.04 µM) and UACC-62 (GI50 < 0.01 µM), in
the NCI’s full panel of 60 human cancer cell lines cytotoxicity evaluation(16), indicating that CCK3 might have the
potential to be tested clinically. To show that CCK3 may
have a longer half-life, a sensitive and robust method has
been developed to study the pharmacokinetics of CCK3
following intravenous administration in rats.

MATERIALS AND METHODS
I. Materials
1-[3-(Furo[3,2-c]quinolin-4-ylamino)phenyl]-ethanoeO-methyl-oxime (CCK3) was synthesized in the laboratory
of School of Medicinal and Applied Chemistry (Kaohsiung
Medical University, Taiwan). 2-Naphthol and tetraglycol
were purchased from Sigma (St. Louis, MO, USA).

39
Journal of Food and Drug Analysis, Vol. 13, No. 1, 2005

O

(A)
1000

N
H

500

CH3
N

mv

N

0

OCH3

Figure 1. Structure of 1-[3-(furo[3,2-C]quinolin-4-ylamino)phenyl]ethanoe-O-methyl oxime (CCK3.)
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Methanol and acetonitrile were obtained from Tedia Co.
(USA). 1-Pentanesulphoric acid and Dichloromethane were
purchased from Merck (Germany). N,N-dimethylacetamide
was obtained from Mallinckrodt (USA). All other
chemicals and solvents were of analytical reagent grade.
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II. Apparatus and Chromatographic Conditions
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An HPLC equipped with a Hitachi model L-7100
pump, a BAS LC-4C electrochemical detector, a Jasco 855AS autosampler and a Merck Lichrocart® C18 column (55
× 4 mm i.d., 3µ ) was used. The mobile phase was a
mixture of 30% acetonitrile, 5% tetrahydrofuran and 65%
of pH 3.0 McIlvaine buffer (v/v/v), at the flow rate of 1.0
mL/min. The effluent from the column was monitored by
an electrochemical detector at +1.0 voltage and 10 nA.
BAS MF 1000 dual glassy-carbon working electrode and
DAS RE6 Ag/AL reference electrode were used.
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III. Drug Standards
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Standard solutions of CCK3 were prepared in
methanol at final concentrations ranging from 100 to
30,000 ng/mL. Plasma standard were prepared using drugfree rat plasma spiked standard solution to obtain the appropriate final concentrations. The internal standard (IS, 2Naphthol, 1 µg/mL) was prepared in methanol.
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IV. Preparation of Plasma Samples
IS solution (0.03 mL) and 4 mL of dichloromethane
were added to aliquots of 0.2 mL of blank, spiked or
plasma samples. The mixture was horizontally shaken for
50 min and centrifuged at 3,000 rpm for 10 min. The
organic layer was transferred to another tube and evaporated to dryness by a vacuum pump. The dry residue was
reconstituted in 0.2 mL of methanol and 0.02 mL of the
clear supernatant that was injected into the HPLC system.
The recovery of CCK3 from plasma was determined
by comparing the peak area obtained from spiked CCK3
samples with that from standards in methanol solution.
For method validation, standards of rat plasma were
prepared and analyzed. Linearity, intra- and inter-assay
precision and accuracy were determined from these data.
The limit of detection (LOD) of CCK3 was determined.
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Figure 2. HPLC chromatograms of CCK3 in rat plasma. (A) blank
plasma (B) plasma spiked with CCK3 (10 ng/mL) and internal
standard (IS) (1 µg/mL) (C) rat plasma extracted for 5 min after IV
administration of 3.97 mg/kg of CCK3.

LOD is the smallest concentration where signals can be distinguished from the noise level, with a typically acceptable
signal-to-noise of 3:1.
V. Determination of CCK3 Pharmacokinetics
Wistar rats weighing 190-220 g were used in the study
(Laboratory Animal Center of National Science Council).
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Rats were anesthetized by intraperitoneal injection of 25%
urethane (3 mL/Kg). CCK3 was dissolved in a aqueous
solution containing 10% N,N-dimethylacetamide, 30%
polyethylene glycol and 30% tetraglycol at final concentrations of 1.6 and 3.2 mg/mL. CCK3 aqueous solution (0.5
mL) was administered via the tail vein at dose of 3.97 and
7.94 mg/kg. Blood samples (0.45 mL) were collected from
the jugular vein at fixed time intervals before and after
CCK3 administration. The blood samples were then centrifuged at 12,000 rpm for 10 min, and then plasma was
immediately separated and stored at -20˚C until analysis.
VI. Analysis of Pharmacokinetic Data
Concentration-time profiles were analyzed using the
PCNONLIN computer program (V4.0, SCI software, USA).
The following pharmacokinetic parameters were assessed:
the area under the plasma concentration-time curves from
time zero to infinity (AUCt-∞), elimination rate constant
(β), half-life for the elimination phase (t1/2β), clearance
(Cl), the volume of distribution (Vdss) and the mean
residence time (MRT). All data were expressed as mean ±
standard derivation. The AUC0-∞ were determined by the
addition of AUC0-t calculated by the trapezoidal rule and
AUCt-∞ calculated by extrapolate to time infinity. The β
value was the terminal slope calculated by linear regression
of the logarithmic value of the terminal phase. The Cl
value was calculated as Dose/AUC0-∞. Area under the first
moment curve (AUMC) was determined as ∫ t•Cp•dt. MRT
was calculated as AUMC/AUC. The student’s t-test statistical test was used to determine the difference among these
data.

RESULTS AND DISCUSSION
The chromatograms of blank plasma and spiked
plasma containing 10 ng/mL of CCK3 and 1 µg/mL of IS
are presented in Figure 2A and B. The peaks are well
separated. Figure 2C shows the chromatogram of extracted
plasma obtained 5 min after IV administration of 3.97
mg/kg of CCK3. The compounds were well resolved
without interference from biological unknown substances.
For ascertainment the CCK3 peak was in fact not partly or
largely due to a metabolite. The photodiode array detector
was used to scan the drug peak. The result showed the
chromatograms of standard drug and extraction from actual
plasma sample were the same (data not shown). The
retention time of CCK3 and IS were 6.5 and 3.8 min,

respectively.
After several trials, it was found that the one-step
liquid-liquid extraction of CCK3 in plasma was satisfactory.
CCK3 was spiked in plasma at final concentrations of 0.05,
1 and 2 µ g/mL, and then extracted by dichloromethane
according the extraction procedure. The analyte recovery
averaged 85.13 ± 4.65% (n = 3), suggesting that the extraction method was reproducible and suitable for the analysis
of plasma samples.
A standard curve, with concentrations ranging from 10
to 3000 ng/mL in 0.2 mL of plasma samples, was constructed. The peak area of CCK3 was divided by the peak
area of internal standard to obtain a peak area ratio. The
data from the standard curves were analyzed using regression analysis to obtain the slope, intercept and correlation
coefficient. The slopes, intercepts and correlation coefficients were 1.86 ± 0.04, -0.0006 ± 0.0456, and 0.9972 ±
0.1588 for intra-day analysis, whereas 1.92 ± 0.03, -0.0010
± 0.0444, and 0.9975 ± 0.1546 for inter-day analysis,
respectively (mean ± SE, n = 3). The correlation coefficients for intra- and inter-day were about 0.99, showing
linearity between these concentration ranges. The lower
limit of detection (LOD) for CCK3 under these conditions
was 5.0 ng/mL. The sensitivity of electrochemical detector
used was about 100 times of Ultraviolet (UV) absorbance
measurement at 262 nm used (data not shown). According
to earlier pharmacokinetic studies of amsacrine and its
analogue(6), the lower limit of quantitation was 40 ng/mL.
Therefore, the electrochemical detector was used to
determine the CCK3 in plasma.
The precision expressed as the coefficients of variation
(CV, %) was calculated for both intra- and inter-day
analysis for each standard concentration. The accuracy was
calculated as a relative error (RE, %). As shown in Table
1, all the CV and RE values were less than 7.69% and
8.16%, respectively, indicating that the assay was suitable
for concentrations ranging from 10 to 3,000 ng/mL. The
range was adequate for estimating plasma pharmacokinetics
(Table 2 and Figure 3).
The drug plasma concentration-time profiles following
intravenous administration of 3.972 and 7.944 mg/Kg
CCK3 are shown in Figure 3. The plasma concentrationtime profiles were analyzed using the PCNONLIN
computer program. The correlation coefficient and AIC
value were 0.9997 and -76.6 for dose of 3.972 mg/Kg, and
0.9965 and -64.9 for dose of 7.944 mg/Kg, respectively,
suggesting that the plasma concentration-time profiles
could be well described by two-compartment open model
with first-order elimination process. The predicted concen-

Table 1. Intra- and inter-day precision (CV, %) and accuracy (RE, %) of determination of CCK3 in rat plasma
Expected
Intra-day
Inter-day
concentration
Observed
C.V. (%)
R.E. (%)a
Observed
C.V. (%)
0.03 µg/mL
0.032 ± 0.003
7.69
6.66
0.031 ± 0.003
7.64
1.00 µg/mL
0.961 ± 0.047
4.95
-3.90
0.931 ± 0.046
4.94
2.00 µg/mL
1.896 ± 0.026
1.37
-5.20
1.837 ± 0.025
1.37
a
R.E. (%) = (observed concentration–expected concentration)/expected concentration × 100%.

R.E. (%)
3.33
-6.90
-8.15
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Plasma concentration (mg/mL)

10
Predicted 7.944 mg/kg
Observed 7.944 mg/kg
Predicted 3.972 mg/kg
Observed 3.972 mg/kg

1

plasma was prolonged up to 1.53 ± 0.28 hr, about 3 folds of
amsacrine. Therefore, CCK3 might have the potential to be
tested clinically.
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Figure 3. Plasma concentration-time curves of CCK3 after intravenous administration of 3.97 and 7.94 mg/kg in rats. Each point represents the mean ± S.D. (n = 3).

Table 2. Pharmacokinetic parameters of CCK3 after intravenous
administration at doses of (3.97 and 7.94 mg/kg) in rats (n = 3)
Parameters
3.97 mg/kg
7.94 mg/kg
A
µg/mL
0.40 ± 0.33
0.90 ± 0.09
0.25 ± 0.10
0.37 ± 0.19
B
µg/mL
α
1/h
5.70 ± 1.75
3.37 ± 2.02
β
1/h
0.53 ± 0.11
0.46 ± 0.25
hr
0.13 ± 0.04
0.28 ± 0.15
t1/2α
hr
1.33 ± 0.24
1.72 ± 0.64
t1/2β
mg•hr/L
0.55 ± 0.20
1.12 ± 0.19a
AUC0-∞
AUC0-∞/Dose
mg•hr/L
0.14 ± 0.05
0.14 ± 0.01
Cl
L/hr
1.59 ± 0.53
1.44 ± 0.24
Vdss
L
2.61 ± 0.95
2.62 ± 0.76
MRT
ht
1.66 ± 0.26
1.89 ± 0.84
a
Student-t test: significant difference (p < 0.05).

tration-time profiles are shown in Figure 3. The pharmacokinetic parameters are listed in Table 2. Comparing these
parameters of CCK3 including half-life, volume of distribution and clearance, no significant difference was shown (p
> 0.05) between these two doses (3.97 and 7.94 mg/kg).
The average elimination half-life of CCK3 was 1.53 ± 0.28
hr, about 3 folds of amsacrine. From the plasma levels, the
values of area under the plasma concentration-time curve
(AUC 0-∞) were 0.55 ± 0.20, and 1.12 ± 0.19 mg •hr/L,
respectively. The AUC0-∞ increased proportionally with
increase in the administration dose.

CONCLUSIONS
An HPLC method was developed to measure CCK3 in
rat plasma. The method was used successfully in a preliminary study of the disposition of CCK3 in rats treated with
dose of 3.972 and 7.944 mg/Kg. The plasma concentration
of CCK3 versus time data was best fitted to a two-compartment open model with first-order elimination process and
linear pharmacokinetics. The half-life of CCK3 in rat
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